PROCEPT BioRobotics Corporation (PRCT) AI Stock Analysis

PROCEPT BioRobotics Corporation is a surgical robotics company that develops, manufactures, and markets the AquaBeam Robotic System. Designed for minimally-invasive urologic surgeries, the platform combines image-guidance technology with Aquablation therapy to treat benign prostatic hyperplasia (BPH) and alleviate lower urinary tract symptoms in male patients. Founded in 2007 and based in Redwood City, California, the company reported an install base of 130 AquaBeam Robotic Systems globally as of December 31, 2021, including 78 deployed in the United States. It employs 888 people.

Annual revenue rose from $34.5M in FY2021 to $308.1M in FY2025, reflecting a 5-year revenue CAGR of 109.0%. Growth has moderated from 346.7% in FY2021 to 37.2% in FY2025. Gross margin expanded from 46.0% in FY2021 to 63.7% in FY2025. Profitability remains negative due to scaling and development costs, including $71.3M in research and development expenses in FY2025. Net income was -$95.6M in FY2025 compared to -$59.9M in FY2021. For the trailing twelve months ended June 30, 2026, revenue totaled $337.3M with quarterly revenue growth of 19.3% year-over-year, while operating margin stood at -32.0% and EPS was -$1.94.

As of June 30, 2026, PROCEPT BioRobotics held $227.9M in cash and short-term investments against $77.5M in total debt, resulting in net cash of $150.4M. Its current ratio was 6.55, and debt-to-equity stood at 0.23. The company generated -$49.0M in operating cash flow and -$58.3M in free cash flow during FY2025. Cash uses in FY2025 included $9.4M in capital expenditures, alongside $6.4M raised from share issuance. Its share count expanded 29.8% over five years.

PRCT trades at a price-to-sales multiple of 3.0x and an enterprise value to revenue multiple of 2.6x, based on a market cap of $1.00B and an enterprise value of $886.5M. Its price-to-sales multiple sits below the 4.1x median of its US-listed Healthcare peers. Over the past year, PRCT declined 48.2% while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 59.7% compared to an 83.0% gain for the benchmark. The shares trade at $17.57, which is 26.7% below their 200-day average.

Wall Street coverage includes 3 Strong Buy, 2 Buy, 9 Hold, 1 Sell, and 0 Strong Sell recommendations. The mean price target is $22.25, representing a 26.6% premium over the last close of $17.57. Consensus projections call for revenue of $395.3M and an EPS of -$1.68 for the fiscal year ending December 31, 2026, followed by $476.3M in revenue and an EPS of -$1.17 in FY2027. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 4, 2026.

This page is an AI-written research summary of PROCEPT BioRobotics Corporation (PRCT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PRCT income statement, PRCT balance sheet, PRCT key metrics, PRCT analyst forecast, PRCT chart. See the PRCT stock overview for the latest quote and news.